Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does USTEKINUMAB Cause Rheumatoid factor positive? 2,538 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 2,538 reports of Rheumatoid factor positive have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 3.0% of all adverse event reports for USTEKINUMAB.

2,538
Reports of Rheumatoid factor positive with USTEKINUMAB
3.0%
of all USTEKINUMAB reports
1,107
Deaths
1,159
Hospitalizations

How Dangerous Is Rheumatoid factor positive From USTEKINUMAB?

Of the 2,538 reports, 1,107 (43.6%) resulted in death, 1,159 (45.7%) required hospitalization, and 1,382 (54.5%) were considered life-threatening.

Is Rheumatoid factor positive Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 2,538 reports have been filed with the FAERS database.

What Other Side Effects Does USTEKINUMAB Cause?

Drug ineffective (12,471) Off label use (10,990) Product dose omission issue (9,405) Fatigue (5,457) Product use issue (5,008) Psoriasis (4,955) Pain (4,872) Rash (4,736) Crohn's disease (4,662) Arthralgia (4,608)

What Other Drugs Cause Rheumatoid factor positive?

METHOTREXATE (4,237) TOCILIZUMAB (4,065) ABATACEPT (4,041) ADALIMUMAB (4,020) LEFLUNOMIDE (3,865) RITUXIMAB (3,793) HYDROXYCHLOROQUINE (3,791) INFLIXIMAB (3,584) ETANERCEPT (3,568) SULFASALAZINE (3,306)

Which USTEKINUMAB Alternatives Have Lower Rheumatoid factor positive Risk?

USTEKINUMAB vs USTEKINUMAB-STBA USTEKINUMAB vs VADADUSTAT USTEKINUMAB vs VALACYCLOVIR USTEKINUMAB vs VALBENAZINE USTEKINUMAB vs VALBENAZINE DITOSYLATE

Related Pages

USTEKINUMAB Full Profile All Rheumatoid factor positive Reports All Drugs Causing Rheumatoid factor positive USTEKINUMAB Demographics